查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1790427

抗生素市場規模、佔有率和趨勢分析報告：按藥物類別、類型、作用機制、地區和細分市場預測，2025 年至 2033 年

Antibiotics Market Size, Share & Trends Analysis Report By Drug Class (Cephalosporin, Fluoroquinolone), By Type (Branded Antibiotics, Generic Antibiotics), By Action Mechanism, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

抗生素市場概況

預計 2024 年全球抗生素市場規模為 530.7 億美元，到 2033 年將達到 740.7 億美元，2025 年至 2033 年的複合年成長率為 3.71%。抗生素市場受細菌感染疾病的流行驅動。

肺炎和支氣管炎等呼吸道感染疾病(RTI) 是最常見的感染疾病之一。例如，CDC 在 2025 年 5 月估計，根據 2024 年至 2025 年的數據，美國將出現 4,700 萬至 8,200 萬例流感病例、2,100 萬人次就診和 64 萬人次住院治療。這些透過每週流感監測和數學建模得出的快報估計數反映了本季的疾病負擔，這通常會導致需要抗生素治療的繼發性細菌感染疾病。根據 BMC Infectious Diseases 通報，尿道感染(UTI) 每年在全球造成超過 1.5 億例，是使用抗生素的主要原因。皮膚和軟組織感染疾病(SSTI)，如蜂窩組織炎，也很重要，尤其是在門診環境中。院內感染 (HAI)，例如艱難困難梭狀芽孢桿菌和抗藥性金黃色葡萄球菌(MRSA)，進一步增加了需求。這些感染疾病的促進因素包括都市化、人口老化以及不斷上升的抗生素抗藥性 (AMR)，這降低了現有治療方法的有效性。在醫療保健資源有限的市場中，高感染率進一步增加了對抗生素的需求，儘管存在抗藥性的挑戰，但仍支撐著市場的成長。

由於高成本、盈利低，抗生素研發 (R&D) 充滿挑戰。開發新型抗生素成本高昂，臨床試驗和監管要求使成本進一步增加，而較短的治療時間限制了收益。不過，針對多重抗藥性腸道細菌的新型抗生素研發正在取得進展，重點是複雜的尿道感染。 CARB-X 於 2025 年 4 月向 ArrePath 支付 370 萬美元。 ArrePath 的人工智慧平台將識別具有獨特作用機制的抑制劑，可能提供口服和靜脈治療選擇，以有效對抗抗菌素抗藥性。例如，輝瑞於 2023 年與艾伯維合作開發新型抗生素組合，並分擔成本和風險。全球 AMR 研發中心也正在協調國際努力，以加強抗生素研發管線。儘管採取了這些措施，但挑戰依然存在，包括抗藥性細菌的迅速出現和新藥的保存期限短。持續的公私合作對於克服這些障礙和確保開發有效的抗生素來對抗抗藥性細菌的出現至關重要。

抗生素市場的主要企業正在採用合併、合作和技術創新等策略來保持競爭力。 2025 年 2 月，諾華以高達 21.5 億美元（包括 9.25 億美元的預付款）收購了中風預防項目 Anthos Therapeutics；禮來收購了 Organovo 用於治療炎症性腸病的 FXR 項目（具體金額未披露）；Almis 以 7.37 億美元現金與免疫介導的免疫介導公司。 2023 年，默克與 Exscientia 合作，投資超過 6.74 億美元，將人工智慧應用於藥物開發、生產和監管流程。此外，默克也與 BenevolentAI 合作，投資數億美元用於人工智慧藥物發現平台。規模較小的公司，例如 Entasis Therapeutics，其肺炎治療藥物 Xacduro 於 2023 年獲得 FDA核准，則瞄準利基市場。像葛蘭素史克這樣的公司也在推廣抗生素管理，鼓勵負責任的使用。然而，學名藥的競爭以及在抗藥性壓力下不斷創新的需求，給盈利帶來了挑戰。這些市場發展反映出一個充滿活力的市場，企業正在平衡成本管理和對新型抗生素的追求，以保持優勢。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章抗生素市場變數、趨勢和範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 抗生素市場分析工具
    • 產業分析—波特五力分析
    • PESTEL分析

第4章：抗生素市場（按藥物類別、估計和趨勢分析）

  • 2024 年及 2033 年藥品類別市場佔有率
  • 細分儀表板
  • 全球抗生素市場：藥物類別展望
  • 2021年至2033年市場規模、預測與趨勢分析
    • 頭孢菌素類
    • 青黴素
    • Fluoroquinolones
    • 大環內酯類
    • 卡巴培南類
    • Aminoglycosides
    • 磺胺類藥物
    • 7-ACA
    • 其他

第5章：抗生素市場類型、預測與趨勢分析

  • 2024 年及 2033 年各類型市場佔有率
  • 細分儀表板
  • 全球抗生素市場：按類型展望
  • 2021年至2033年市場規模、預測與趨勢分析
    • 品牌抗生素
    • 非專利藥

第6章：抗生素市場的作用機制、估計與趨勢分析

  • 2024年及2033年作用機制市場佔有率
  • 細分儀表板
  • 全球抗生素市場：作用機制展望
  • 2021年至2033年市場規模、預測與趨勢分析
    • 細胞壁合成抑制劑
    • 蛋白質合成抑制劑
    • DNA合成抑制劑
    • RNA合成抑制劑
    • 肌酸抑制劑
    • 其他

第7章抗生素市場：區域估計/趨勢分析

  • 2024 年及 2033 年區域市場佔有率分析
  • 區域市場儀表板
  • 全球區域市場概況
  • 2021-2033 年市場規模、預測趨勢分析
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭態勢

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商格局
    • 主要經銷商和通路合作夥伴名單
    • 2024年主要企業市場佔有率分析
    • AbbVie, Inc.
    • Pfizer Inc.
    • Novartis AG
    • Merck & Co., Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Lupin Pharmaceuticals, Inc.
    • Viatris, Inc.
    • Melinta Therapeutics LLC
    • Cipla, Inc.
    • Shionogi & Co., Ltd.
    • KYORIN Pharmaceutical Co., Ltd.
    • GSK plc
    • Nabriva Therapeutics PLC
Product Code: GVR-1-68038-149-8

Antibiotics Market Summary

The global antibiotics market size was estimated at USD 53.07 billion in 2024 and is projected to reach USD 74.07 billion by 2033, growing at a CAGR of 3.71% from 2025 to 2033, major factor contributing to market growth. The antibiotics market is driven by the prevalence of bacterial infections.

Respiratory tract infections (RTIs), such as pneumonia and bronchitis, are among the most widespread, for instance, in May 2025, the CDC estimated that the U.S. experienced between 47-82 million flu illnesses, 21 million medical visits, and 640,000 hospitalizations, based on data from 2024 - 2025. These preliminary figures, derived from weekly influenza surveillance and mathematical modeling, reflect the season's disease burden, often leading to secondary bacterial infections requiring antibiotics. Urinary tract infections (UTIs) follow closely, with over 150 million cases annually worldwide, according to BMC Infectious Diseases, making them a leading cause of antibiotic use. Skin and soft tissue infections (SSTIs), such as cellulitis, are also significant, especially in outpatient care. Hospital-acquired infections (HAIs), including Clostridium difficile and methicillin-resistant Staphylococcus aureus (MRSA), further increase demand. These infections are fueled by urbanization, aging populations, and rising antimicrobial resistance (AMR), which reduces the efficacy of existing treatments. High infection rates in developing regions with limited healthcare access further amplify the need for antibiotics, sustaining market growth despite resistance challenges.

Research and development (R&D) in antibiotics face hurdles due to high costs and low profitability. Developing new antibiotics is expensive, with clinical trials and regulatory demands adding to the burden, while short treatment durations limit returns. However, initiatives such as in April 2025, CARB-X awarded ArrePath USD 3.7 million to develop a novel antibiotic targeting multidrug-resistant Enterobacterales, focusing on complicated urinary tract infections. Using an AI-driven platform, ArrePath identified inhibitors with a unique mechanism, potentially offering oral and IV treatment options to combat antimicrobial resistance effectively. For example, Pfizer partnered with AbbVie in 2023 to develop novel antibiotic combinations, sharing costs and risks. The Global AMR R&D Hub also coordinates international efforts to bolster the antibiotic pipeline. Despite these measures, challenges persist, as resistance develops quickly, reducing the lifespan of new drugs. Sustained public-private collaboration is critical to overcoming these barriers and ensuring the development of effective antibiotics to combat rising resistance.

Key players in the antibiotics market employ strategies such as mergers, partnerships, and innovation to stay competitive. In February 2025, key biotech deals included Novartis acquiring Anthos Therapeutics for up to $2.15 billion ($925 million upfront) for its stroke prevention program, Eli Lilly buying Organovo's FXR program for inflammatory bowel disease (terms undisclosed), and the merger of Alumis and Acelyrin, focusing on immune-mediated diseases with a $737 million cash runway. In 2023, Merck invested over USD 674 million partnering with Exscientia to apply AI in drug development, manufacturing, and regulatory processes. Additionally, Merck joined forces with BenevolentAI, investing hundreds of millions more in AI drug discovery platforms. Smaller firms like Entasis Therapeutics, which gained FDA approval for Xacduro in 2023 for pneumonia, target niche markets. Companies such as GSK also promote antibiotic stewardship to encourage responsible use. However, generic competition and the need for constant innovation amid resistance pressures challenge profitability. These developments reflect a dynamic market where firms balance cost management with the pursuit of novel antibiotics to maintain their edge.

Global Antibiotics Market Report Segmentation

This report forecasts revenue growth at global, regional & country levels and provides an analysis on the industry trends in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the global antibiotics market report on the basis of drug class, type, action mechanism, and region:

  • Drug Class Outlook (Revenue in USD Million, 2021 - 2033)
  • Cephalosporin
  • Penicillin
  • Fluoroquinolone
  • Macrolides
  • Carbapenems
  • Aminoglycosides
  • Sulfonamides
  • 7-ACA
  • Others
  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Branded Antibiotics
  • Generic Antibiotics
  • Action Mechanism Outlook (Revenue, USD Million, 2021 - 2033)
  • Cell Wall Synthesis Inhibitors
  • Protein Synthesis Inhibitors
  • DNA Synthesis Inhibitors
  • RNA Synthesis Inhibitors
  • Mycolic Acid Inhibitors
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • Thailand
    • South Korea
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Type
    • 1.2.3. Action Mechanism
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug Class
    • 2.2.2. Type
    • 2.2.3. Action Mechanism
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Antibiotics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Development of advanced products
      • 3.2.1.2. Increasing prevalence of infectious diseases
      • 3.2.1.3. Growing collaborations for development of antibiotics
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High number of patent expirations
      • 3.2.2.2. High R&D cost
  • 3.3. Antibiotics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Antibiotics Market: Drug Class Estimates & Trend Analysis

  • 4.1. Drug Class Market Share, 2024 & 2033
  • 4.2. Segment Dashboard
  • 4.3. Global Antibiotics Market by Drug Class Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
    • 4.4.1. Cephalosporin
      • 4.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.2. Penicillin
      • 4.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.3. Fluoroquinolone
      • 4.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.4. Macrolides
      • 4.4.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.5. Carbapenems
      • 4.4.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.6. Aminoglycosides
      • 4.4.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.7. Sulfonamides
      • 4.4.7.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.8. 7-ACA
      • 4.4.8.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.9. Others
      • 4.4.9.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Antibiotics Market: Type Estimates & Trend Analysis

  • 5.1. Type Market Share, 2024 & 2033
  • 5.2. Segment Dashboard
  • 5.3. Global Antibiotics Market by Type Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
    • 5.4.1. Branded Antibiotics
      • 5.4.1.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.2. Generic Antibiotics
      • 5.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Antibiotics Market: Action Mechanism Estimates & Trend Analysis

  • 6.1. Action Mechanism Market Share, 2024 & 2033
  • 6.2. Segment Dashboard
  • 6.3. Global Antibiotics Market by Action Mechanism Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
    • 6.4.1. Cell Wall Synthesis Inhibitors
      • 6.4.1.1. Market estimates and forecasts 2021 to 2033 (USD million)
    • 6.4.2. Protein Synthesis Inhibitors
      • 6.4.2.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.4.3. DNA Synthesis Inhibitors
      • 6.4.3.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.4.4. RNA Synthesis Inhibitors
      • 6.4.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.4.5. Mycolic Acid Inhibitors
      • 6.4.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.4.6. Others
      • 6.4.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Antibiotics Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2033
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
  • 7.5. North America
    • 7.5.1. U.S.
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.2. Canada
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.5.3. Mexico
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6. Europe
    • 7.6.1. UK
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.2. Germany
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.3. France
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.4. Italy
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework/ reimbursement structure
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.5. Spain
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework/ reimbursement structure
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.6. Norway
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework/ reimbursement structure
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.7. Sweden
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Regulatory framework/ reimbursement structure
      • 7.6.7.3. Competitive scenario
      • 7.6.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.6.8. Denmark
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Regulatory framework/ reimbursement structure
      • 7.6.8.3. Competitive scenario
      • 7.6.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Japan
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.2. China
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.3. India
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.4. Australia
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.5. South Korea
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Regulatory framework/ reimbursement structure
      • 7.7.5.3. Competitive scenario
      • 7.7.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.7.6. Thailand
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Regulatory framework/ reimbursement structure
      • 7.7.6.3. Competitive scenario
      • 7.7.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Brazil
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Regulatory framework/ reimbursement structure
      • 7.8.1.3. Competitive scenario
      • 7.8.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.8.2. Argentina
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework/ reimbursement structure
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.9. MEA
    • 7.9.1. South Africa
      • 7.9.1.1. Key country dynamics
      • 7.9.1.2. Regulatory framework/ reimbursement structure
      • 7.9.1.3. Competitive scenario
      • 7.9.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.9.2. Saudi Arabia
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Regulatory framework/ reimbursement structure
      • 7.9.2.3. Competitive scenario
      • 7.9.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.9.3. UAE
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Regulatory framework/ reimbursement structure
      • 7.9.3.3. Competitive scenario
      • 7.9.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
    • 7.9.4. Kuwait
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Regulatory framework/ reimbursement structure
      • 7.9.4.3. Competitive scenario
      • 7.9.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2024
    • 8.3.4. AbbVie, Inc.
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Pfizer Inc.
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Novartis AG
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Merck & Co., Inc.
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Teva Pharmaceutical Industries Ltd.
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Lupin Pharmaceuticals, Inc.
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Viatris, Inc.
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Melinta Therapeutics LLC
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Cipla, Inc.
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. Shionogi & Co., Ltd.
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Product benchmarking
      • 8.3.13.4. Strategic initiatives
    • 8.3.14. KYORIN Pharmaceutical Co., Ltd.
      • 8.3.14.1. Company overview
      • 8.3.14.2. Financial performance
      • 8.3.14.3. Product benchmarking
      • 8.3.14.4. Strategic initiatives
    • 8.3.15. GSK plc
      • 8.3.15.1. Company overview
      • 8.3.15.2. Financial performance
      • 8.3.15.3. Product benchmarking
      • 8.3.15.4. Strategic initiatives
    • 8.3.16. Nabriva Therapeutics PLC
      • 8.3.16.1. Company overview
      • 8.3.16.2. Financial performance
      • 8.3.16.3. Product benchmarking
      • 8.3.16.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America Antibiotics market, by region, 2021 - 2033 (USD Million)
  • Table 3 North America Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 4 North America Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 5 North America Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 6 U.S. Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 7 U.S. Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 8 U.S. Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 9 Canada Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 10 Canada Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 11 Canada Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 12 Mexico Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 13 Mexico Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 14 Mexico Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 15 Europe Antibiotics market, by region, 2021 - 2033 (USD Million)
  • Table 16 Europe Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 17 Europe Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 18 Europe Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 19 Germany Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 20 Germany Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 21 Germany Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 22 UK Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 23 UK Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 24 UK Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 25 France Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 26 France Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 27 France Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 28 Italy Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 29 Italy Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 30 Italy Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 31 Spain Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 32 Spain Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 33 Spain Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 34 Denmark Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 35 Denmark Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 36 Denmark Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 37 Sweden Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 38 Sweden Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 39 Sweden Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 40 Norway Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 41 Norway Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 42 Norway Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 43 Asia Pacific Antibiotics market, by region, 2021 - 2033 (USD Million)
  • Table 44 Asia Pacific Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 45 Asia Pacific Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 46 Asia Pacific Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 47 China Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 48 China Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 49 China Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 50 Japan Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 51 Japan Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 52 Japan Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 53 India Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 54 India Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 55 India Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 56 South Korea Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 57 South Korea Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 58 South Korea Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 59 Australia Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 60 Australia Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 61 Australia Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 62 Thailand Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 63 Thailand Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 64 Thailand Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 65 Latin America Antibiotics market, by region, 2021 - 2033 (USD Million)
  • Table 66 Latin America Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 67 Latin America Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 68 Latin America Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 69 Brazil Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 70 Brazil Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 71 Brazil Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 72 Argentina Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 73 Argentina Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 74 Argentina Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 75 MEA Antibiotics market, by region, 2021 - 2033 (USD Million)
  • Table 76 MEA Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 77 MEA Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 78 MEA Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 79 South Africa Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 80 South Africa Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 81 South Africa Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 82 Saudi Arabia Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 83 Saudi Arabia Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 84 Saudi Arabia Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 85 UAE Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 86 UAE Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 87 UAE Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)
  • Table 88 Kuwait Antibiotics market, by drug class, 2021 - 2033 (USD Million)
  • Table 89 Kuwait Antibiotics market, by type, 2021 - 2033 (USD Million)
  • Table 90 Kuwait Antibiotics market, by action mechanism, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Antibiotics market: market outlook
  • Fig. 14 Antibiotics competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Antibiotics market driver impact
  • Fig. 20 Antibiotics market restraint impact
  • Fig. 21 Antibiotics market strategic initiatives analysis
  • Fig. 22 Antibiotics market: Drug Class movement analysis
  • Fig. 23 Antibiotics market: Drug Class outlook and key takeaways
  • Fig. 24 Cephalosporin market estimates and forecast, 2021 - 2033
  • Fig. 25 Penicillin market estimates and forecast, 2021 - 2033
  • Fig. 26 Fluoroquinolone market estimates and forecast, 2021 - 2033
  • Fig. 27 Macrolides market estimates and forecast, 2021 - 2033
  • Fig. 28 Carbapenems market estimates and forecast, 2021 - 2033
  • Fig. 29 Aminoglycosides market estimates and forecast, 2021 - 2033
  • Fig. 30 Sulfonamides market estimates and forecast, 2021 - 2033
  • Fig. 31 7-ACA market estimates and forecast, 2021 - 2033
  • Fig. 32 Others market estimates and forecast, 2021 - 2033
  • Fig. 33 Antibiotics Market: Type movement Analysis
  • Fig. 34 Antibiotics market: Type outlook and key takeaways
  • Fig. 35 Branded Antibiotics market estimates and forecasts, 2021 - 2033
  • Fig. 36 Generic Antibiotics market estimates and forecasts,2021 - 2033
  • Fig. 37 Antibiotics market: Action Mechanism movement analysis
  • Fig. 38 Antibiotics market: Action Mechanism outlook and key takeaways
  • Fig. 39 Cell Wall Synthesis Inhibitors market estimates and forecasts, 2021 - 2033
  • Fig. 40 Protein Synthesis Inhibitors market estimates and forecasts,2021 - 2033
  • Fig. 41 DNA Synthesis Inhibitors market estimates and forecasts,2021 - 2033
  • Fig. 42 RNA Synthesis Inhibitors market estimates and forecasts, 2021 - 2033
  • Fig. 43 Mycolic Acid Inhibitors market estimates and forecasts,2021 - 2033
  • Fig. 44 Others market estimates and forecasts, 2021 - 2033
  • Fig. 45 Global Antibiotics market: Regional movement analysis
  • Fig. 46 Global Antibiotics market: Regional outlook and key takeaways
  • Fig. 47 Global Antibiotics market share and leading players
  • Fig. 48 North America market share and leading players
  • Fig. 49 Europe market share and leading players
  • Fig. 50 Asia Pacific market share and leading players
  • Fig. 51 Latin America market share and leading players
  • Fig. 52 Middle East & Africa market share and leading players
  • Fig. 53 North America: SWOT
  • Fig. 54 Europe SWOT
  • Fig. 55 Asia Pacific SWOT
  • Fig. 56 Latin America SWOT
  • Fig. 57 MEA SWOT
  • Fig. 58 North America, by country
  • Fig. 59 North America
  • Fig. 60 North America market estimates and forecasts, 2021 - 2033
  • Fig. 61 U.S.
  • Fig. 62 U.S. market estimates and forecasts, 2021 - 2033
  • Fig. 63 Canada
  • Fig. 64 Canada market estimates and forecasts, 2021 - 2033
  • Fig. 65 Mexico
  • Fig. 66 Mexico market estimates and forecasts, 2021 - 2033
  • Fig. 67 Europe
  • Fig. 68 Europe market estimates and forecasts, 2021 - 2033
  • Fig. 69 UK
  • Fig. 70 UK market estimates and forecasts, 2021 - 2033
  • Fig. 71 Germany
  • Fig. 72 Germany market estimates and forecasts, 2021 - 2033
  • Fig. 73 France
  • Fig. 74 France market estimates and forecasts, 2021 - 2033
  • Fig. 75 Italy
  • Fig. 76 Italy market estimates and forecasts, 2021 - 2033
  • Fig. 77 Spain
  • Fig. 78 Spain market estimates and forecasts, 2021 - 2033
  • Fig. 79 Denmark
  • Fig. 80 Denmark market estimates and forecasts, 2021 - 2033
  • Fig. 81 Sweden
  • Fig. 82 Sweden market estimates and forecasts, 2021 - 2033
  • Fig. 83 Norway
  • Fig. 84 Norway market estimates and forecasts, 2021 - 2033
  • Fig. 85 Asia Pacific
  • Fig. 86 Asia Pacific market estimates and forecasts, 2021 - 2033
  • Fig. 87 China
  • Fig. 88 China market estimates and forecasts, 2021 - 2033
  • Fig. 89 Japan
  • Fig. 90 Japan market estimates and forecasts, 2021 - 2033
  • Fig. 91 India
  • Fig. 92 India market estimates and forecasts, 2021 - 2033
  • Fig. 93 Thailand
  • Fig. 94 Thailand market estimates and forecasts, 2021 - 2033
  • Fig. 95 South Korea
  • Fig. 96 South Korea market estimates and forecasts, 2021 - 2033
  • Fig. 97 Australia
  • Fig. 98 Australia market estimates and forecasts, 2021 - 2033
  • Fig. 99 Latin America
  • Fig. 100 Latin America market estimates and forecasts, 2021 - 2033
  • Fig. 101 Brazil
  • Fig. 102 Brazil market estimates and forecasts, 2021 - 2033
  • Fig. 103 Argentina
  • Fig. 104 Argentina market estimates and forecasts, 2021 - 2033
  • Fig. 105 Rest of Latin America
  • Fig. 106 Rest of Latin America market estimates and forecasts, 2021 - 2033
  • Fig. 107 Middle East and Africa
  • Fig. 108 Middle East and Africa market estimates and forecasts, 2021 - 2033
  • Fig. 109 South Africa
  • Fig. 110 South Africa market estimates and forecasts, 2021 - 2033
  • Fig. 111 Saudi Arabia
  • Fig. 112 Saudi Arabia market estimates and forecasts, 2021 - 2033
  • Fig. 113 UAE
  • Fig. 114 UAE market estimates and forecasts, 2021 - 2033
  • Fig. 115 Kuwait
  • Fig. 116 Kuwait market estimates and forecasts, 2021 - 2033
  • Fig. 117 Market share of key market players- Antibiotics market